What Can You Expect at the Pioneering Oligonucleotide Therapeutics Summit?
The 2nd Oligonucleotide Therapeutics Summit will bring together the scientists and decision-makers solving the field's biggest challenges. Across two deep-dive, technical, conference days and a dedicated workshop day, you will get hands-on with breakthrough strategies in blood-brain barrier engineering, AI-designed miniproteins, and ligand discovery beyond GalNAc and TfR for extrahepatic delivery. Expect candid case studies, live scientific debate, and direct access to a speaker faculty where you can benchmark against peers! This is where you will build the connections and insight to move your programme forward.
Unmissable Event Highlights: What to Expect
A Brand-New Pre-Conference Workshop Day
For the first time, delegates can go deep on oligonucleotide delivery before the main agenda even begins. Two hands-on workshops, comparing today's leading extrahepatic oligonucleotide delivery strategies, and building the next generation of oligonucleotide conjugates, ligands and linkers, give you a practical framework to take home, not just a seat in the audience.
Live Formats Built for Genuine Debate
Two new interactive formats put the field's most divisive oligonucleotide questions to the test. Watch saRNA, small activating RNA, face direct, moderator-led cross-examination in a live Hot Seat over whether it's a genuine oligonucleotide breakthrough or unproven promise. Bring your own conjugate ligand or linker design challenge to a small-group Innovation Lab to work through it with peers solving the same oligonucleotide delivery problem.
Confronting Endosomal Escape & the Depot Effect Head-On
Three dedicated sessions unpack why tissue accumulation doesn't always mean activity, so you can walk away knowing how to diagnose and design around one of the field's most under-discussed bottlenecks in your own programme, with perspectives from UCSD, UMass Chan Medical School and NanoDe Therapeutics
Beyond the Liver, Beyond CNS
Explore a genuinely disease-agnostic programme spanning oncology, rare disease, metabolic and CNS indications, alongside hard-won industry experience from Vivatides, Evercrisp and Cellado Bio, so you leave with delivery strategies you can apply across your whole pipeline, not just a single indication
An Unfiltered Look Inside Pharma Business Development
A rare, on-the-record conversation with external innovation leaders on exactly what makes an oligonucleotide programme stand out for partnership, in-licensing or acquisition, the closed-door discussion three separate research contacts asked for by name, to know precisely what BD teams are actually looking for before you pitch them
What's New for 2026
Explore the Full Event Guide
- Get the full agenda, speaker line-up, and session breakdown for the Oligonucleotide Therapeutics Summit, and start planning which sessions on extrahepatic delivery, conjugate design, or next-gen chemistry are must-attends for your programme
- See the breadth of modalities and disease areas on the agenda, spanning metabolic, neurological, cardiovascular and oncology applications, and pinpoint where oligonucleotide technology could unlock your next target
- Meet the faculty shaping the field, from Directors of Oligonucleotide Chemistry to VPs of Platform Discovery and CSOs, with over half our confirmed speakers holding Director-level roles or above
- Check out sessions unveiling entirely new, never-before-seen data, including groundbreaking work on aptamers, before it's presented anywhere else
- See who else is in the room, from CMC leads to translational biology VPs across pharma and biotech, and start planning the conversations worth having before you arrive
Attending Companies Include
Explore the Agenda
Discover innovative oligonucleotide chemistry and delivery breakthroughs across our expert-led sessions, workshops, and panel discussions.
Partner With Us
Position your brand as a leading solution providers and expert at the heart of oligonucleotide drug development.
Join Oligonucleotide Experts
Connect with scientists and decision-makers driving the next generation of ASO and RNA-based therapeutics during dedicated networking sessions.